UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i March 16, 2023

 

BIOCEPT, INC.

(Exact name of registrant as specified in its charter)

 

 

i Delaware		i 001-36284		i 80-0943522
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

i 9955 Mesa Rim Road,  i San Diego,  i CA		i 92121
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:  i (858)  i 320-8200

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, par value $0.0001 per share		i BIOC		i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On March 16, 2023, Michael C. Dugan, M.D., the Senior Vice President, Chief Medical Officer and Medical Director of Biocept, Inc. (the “Company”), was terminated, effective March 17, 2023.

Effective March 17, 2023, the Company has promoted its Associate Medical Director, Nathaniel Sweed, M.D., to Medical Director. The Company has also designated a new laboratory medical director of the Company’s CLIA-certified, CAP-accredited clinical laboratory in San Diego, California.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				BIOCEPT, INC.
Dated: March 20, 2023				By:		/s/ Samuel D. Riccitelli
				Name:		Samuel D. Riccitelli
				Title:		Interim President and Chief Executive Officer